Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 6, 2010, Pages 730-737

  Traynor, M J ^a   Turner, R B ^b   Evans, C R G ^b   Khengar, R H ^c   Jones, S A ^c   Brown, M B ^a,b  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b MEDPHARM LTD   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Nail; Onychomycosis; Permeation enhancer; Terbinafine; Ungual

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMOROLFINE; CICLOPIROXOLAMINE; PAINT; TERBINAFINE; ANTIFUNGAL AGENT; CICLOPIROX; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DERMATOPHYTE; DRUG PENETRATION; HUMAN; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; NAIL; ONYCHOMYCOSIS; TRICHOPHYTON RUBRUM; CADAVER; IN VITRO STUDY; METABOLISM; MICROBIOLOGY; NAIL DISEASES; PERMEABILITY; TOPICAL DRUG ADMINISTRATION;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; CADAVER; HUMANS; IN VITRO TECHNIQUES; MORPHOLINES; NAIL DISEASES; NAILS; NAPHTHALENES; ONYCHOMYCOSIS; PERMEABILITY; PYRIDONES;

EID: 77953595229     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.06.0009     Document Type: Article

References (38)

1. Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1993 129: 101 109.
2. Editorial. Prevalence, morbidity, and cost of dermatological diseases. J Invest Dermatol 1979 73 (5 Pt 2 395 401.
3. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998 11: 415 429.
4. Ginter G et al. [Increasing frequency of onychomycoses-is there a change in the spectrum of infectious agents?]. Mycoses 1996 39 (Suppl 1) 118 122.
5. Goodfield MJD et al. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992 304: 1151 1154.
6. Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995 133: 699 703.
7. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992 126 (Suppl 39) 23 27.
8. Sais G et al. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995 132: 758 761.
9. Repka MA et al. Nail morphology studies as assessments for onychomycosis treatment modalities. Int J Pharm 2002 245: 25 36.
10. Kobayashi Y et al. Drug permeation through the three layers of the human nail plate. J Pharm Pharmacol 1999 51: 271 278.
11. Blank H et al. The treatment of dermatomycoses with orally administered griseofulvin. AMA Arch Dermatol 1959 79: 259 266.
12. Van der Schroeff JG et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992 126 (Suppl.: 36 39.
13. Ajit C et al. Terbinafine-associated hepatotoxicity. Am J Med Sci 2003 325: 292 295.
14. Goodfield MJD et al. Treatment of dermatophyte infection of the finger-and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol 1989 121: 753 757.
15. Chambers WM et al. Terbinafine-induced hepatic dysfunction. Eur J Gastroenterol Hepatol 2001 13: 1115 1118.
16. Bohn M et al. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J Am Podiatr Med Assoc 2000 90: 491 494.
17. Bohn M et al. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000 43 (4 Suppl.: S57 S69.
18. Gupta AK et al. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol 2000 43 (4 Suppl.: S96 S102.
19. Gupta AK et al. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. [see comment]. J Am Acad Dermatol 2000 43 (4 Suppl.: S70 S80.
20. Gupta AK, Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000 43 (4 Suppl.: S81 S95.
21. Seebacher C. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis. Mycoses 2003 46: 506 510.
22. Akomeah FK et al. Variability in human skin permeability in vitro: comparing penetrants with different physicochemical properties. J Pharm Sci 2007 96: 824 834.
23. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001 14: 101 114.
24. Bos JD et al. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000 9: 165 169.
25. Brown MB et al. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006 13: 175 187.
26. Brown MB et al. Transdermal drug delivery systems: skin perturbation devices. Methods Mol Biol 2008 437: 119 139.
27. Hadgraft J. Skin, the final frontier. Int J Pharm 2001 224: 1 18.
28. Kezic S. Human in vivo studies of dermal penetration, their relation to in vitro prediction. In: Brain KR, Walters KA eds. Perspectives in Percutaneous Penetration.
29. Scott RC, Dugard PH. The properties of skin as a diffusion barrier and route for absorption. In: Greaves MW, Schuster S. eds. Pharmacology of the Skin I.
30. Wessel S et al. Hydration of human nails investigated by NIR-FT-Raman spectroscopy. Biochim Biophys Acta 1999 1433: 210 216.
31. Monti D et al. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005 31: 11 17.
32. Malhotra GG, Zatz JL. Investigation of nail permeation enhancement by chemical modification using water as a probe. J Pharm Sci 2002 91: 312 323.
33. Murdan S, Murdan S. Enhancing the nail permeability of topically applied drugs. Exp Opin Drug Deliv 2008 5: 1267 1282.
34. Khengar RH et al. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers. Pharm Res 2007 24: 2207 2212.
35. Brown MB et al. Overcoming the nail barrier: a systematic investigation of ungual chemical penetration enhancement. Int J Pharm 2009 370: 61 67.
36. Bolduc C, Shapiro J. Hair care products: waving, straightening, conditioning, and coloring. Clin Dermatol 2001 19: 431 436.
37. Wickett RR. Permanent waving and straightening of hair. Cutis 1987 39: 496 497.
38. Einarson TR et al. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996 9: 307 320.